Mobility disability
Disease1 paper3 findings
- Human trial1
Interventions
1Multicomponent lifestyle intervention
no changein humans1HR 1.06
1 study
Multicomponent lifestyle intervention
no changein humans1HR 1.06
Multicomponent lifestyle intervention has no effect on mobility disability in humans (HR 1.06, 95% CI 0.65-1.71).
Human trialin benzodiazepine users with SPPB scores 3 to 7physical exercise and nutritional counselling
Does the use of benzodiazepine influence the effectiveness of lifestyle intervention? Secondary analysis from the Sarcopenia and Physical fRailty iN older people strategies (SPRINTT) trial · Age and ageing · 3 Aug 2026
Associations
2Multicomponent lifestyle intervention
downin humans1HR 0.8
1 study
Multicomponent lifestyle intervention
downin humans1HR 0.8
Multicomponent lifestyle intervention lowers the risk of mobility disability in humans (HR 0.80, 95% CI 0.66-0.97).
Human trialin non-users of benzodiazepines with SPPB scores 3 to 7physical exercise and nutritional counselling
Does the use of benzodiazepine influence the effectiveness of lifestyle intervention? Secondary analysis from the Sarcopenia and Physical fRailty iN older people strategies (SPRINTT) trial · Age and ageing · 3 Aug 2026
Benzodiazepines
upin humans1
1 study
Benzodiazepines
upin humans1
Benzodiazepines are associated with mobility disability in humans (55.0% vs 43.6%).
Human trialat baselinen = 1,506
Does the use of benzodiazepine influence the effectiveness of lifestyle intervention? Secondary analysis from the Sarcopenia and Physical fRailty iN older people strategies (SPRINTT) trial · Age and ageing · 3 Aug 2026
Trial sponsors
Company1 trialPhase 2239 people
Wake Forest University Health Sciences
2 trials48 people
1 trial300 people
Funding
National Institute of Child Health and Human DevelopmentUS$664.9k1 grant since 2026